Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11825493 | 0.96 | GLA (0.68) | USP2ABCB1GLAL3MBTL1ALDH1A1 | |
| SCHEMBL5318188 | 0.93 | SMN1; SMN2 (0.64) | USP2ABCB1GLAL3MBTL1ALDH1A1 | |
| Ethyl Bromo Acetate SCHEMBL5783532 | 0.91 | USP2 (0.58) | USP2ABCB1GLAL3MBTL1ALDH1A1 | |
| SCHEMBL2871937 | 0.91 | MAPT (0.62) | USP2ABCB1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL9369313 | 0.90 | USP2 (0.57) | USP2ABCB1GLAL3MBTL1ALDH1A1 | |
| SCHEMBL30717645 | 0.90 | USP2 (0.61) | USP2ABCB1GLAL3MBTL1ALDH1A1 | |
| SCHEMBL3154126 | 0.89 | L3MBTL1 (0.62) | USP2ABCB1GLAL3MBTL1ALDH1A1 | |
| SCHEMBL3259595 | 0.89 | USP2 (0.60) | USP2ABCB1GLAL3MBTL1ALDH1A1 | |
| SCHEMBL2011265 | 0.88 | USP2 (0.58) | USP2ABCB1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL257483 | 0.88 | USP2 (0.58) | USP2ABCB1L3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | USP2 4581/4885ABCB1 568/4885GLA 1865/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | USP2 4581/4885ABCB1 568/4885GLA 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.